VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference

Rhea-AI Summary

VYNE Therapeutics announced that David Domzalski, CEO, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. His presentation, a fireside chat, is scheduled for September 28 at 4 PM ET and will be available for archiving for 90 days. VYNE aims to enhance patient lives through innovative treatments for immuno-inflammatory conditions, with ongoing projects including FCD105 for acne and FMX114 for atopic dermatitis. VYNE has received FDA approvals for AMZEEQ and ZILXI, both minocycline topical products.

BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, to take place September 27^th – 30^th.

The presentation will take the form of a fireside chat, which will be archived here for 90 days. Management will also be available for 1-on-1 meetings with investors.

Presentation details
Date:	September 28th
Time:	4pm ET
Webcast:	https://wsw.com/webcast/cantor12/vyne/2115540

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s unique and proprietary pipeline includes Phase 3 ready FCD105 (3% minocycline and 0.3% adapalene) for the treatment of moderate-to-severe acne vulgaris, FMX114 for the treatment of mild-to-moderate atopic dermatitis and a library of bromodomain & extra-terminal domain inhibitors in both topical and oral forms for the treatment of major immuno-inflammatory conditions and rare skin diseases. VYNE has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com

Tyler Zeronda
Chief Financial Officer
VYNE Therapeutics
908-458-9106
Tyler.Zeronda@vynetx.com

FAQ

When is VYNE's presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference?

VYNE's presentation is scheduled for September 28, 2021, at 4 PM ET.

What is the focus of VYNE Therapeutics' research?

VYNE focuses on developing innovative therapies for immuno-inflammatory conditions and skin diseases.

What are AMZEEQ and ZILXI?

AMZEEQ is the world's first topical minocycline, while ZILXI is the first topical product approved for rosacea.

How can investors access VYNE's conference presentation?

Investors can access the conference presentation via a webcast, available for 90 days after the event.

Who will be participating in VYNE's conference presentation?

David Domzalski, CEO of VYNE Therapeutics, will present at the conference.